Steve Kanner | Chief Scientific Officer
Caribou Biosciences

Steve Kanner, Chief Scientific Officer, Caribou Biosciences

Steve is the Chief Scientific Officer of Caribou Biosciences responsible for R&D activities related to therapeutic discovery and development.  Before joining Caribou, Steve served in positons of increasing responsibility in both oncology and immunology/inflammation drug discovery at Bristol-Myers Squibb, Agensys, and Astex Pharmaceuticals, and was most recently VP, Head of Biology at Arrowhead Pharmaceuticals leading a department in discovery of RNAi therapeutics for oncology, genetic diseases and other indications.  Steve has authored over 80 publications in both peer-reviewed journals and books, and is an inventor on multiple patents and patent applications.  Steve earned his undergraduate degree in Genetics from the University of California, Berkeley, his Ph.D. in Immunology and Microbiology from the University of Miami?s Miller School of Medicine, and did post-doctoral work in oncology at the University of Virginia.


Day 1: Wednesday 19th May 2021 - Cell Therapy @ 15:30

Panel: Tackling solid tumours

·Hurdles to solid tumour cell therapy and novel strategies to overcome·Autologous and allogeneic cell therapy for solid tumours·Potential role for combination cellular therapies

Day 2: Thursday 20th May 2021 - Gene Therapy @ 16:00

CRISPR’s Progress for Patients: Clinical Development of Therapies

Day 2: Thursday 20th May 2021 - Gene Therapy @ 16:30

Q&A panel: what’s next in ex-vivo gene therapy and gene editing?

last published: 10/May/21 08:45 GMT

back to speakers